Pay in 4 interest-free payments of $6.76 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Instead, its about making sustainable changes, like incorporating more whole foods and finding movement you enjoy
These therapies are typically personalized based on a persons goals, lab results, and overall health profile.
New Obesity Drugs: Why Wave-007 Is Stealing the Spotlight Episode Timeline & Main Topics 00:00 Opening & Community Update First week doing the podcast fully live thanks to the On The Pen community Overview of why this weeks news is a major turning point in obesity medicine 02:30 Introducing the One-and-Done Obesity Drug (Wave Life Sciences) WVE-007 early data drops Why this therapy is unlike GLP-1s or any nutrient-stimulated hormone Fat loss results and lean-mass increase 06:30 How Wave-007 Works: INHBE Gene Silencing Mechanism behind visceral fat reduction Why this shifts the field toward quality of weight loss 09:15 Why Lean-Mass Preservation Matters Current GLP-1 medications and muscle loss Why women dominate trial enrollment and the larger implications Medicare patients and the coming wave of GLP-1 coverage 13:45 The Future of Maintenance Therapies Fractyl Health Revita results Lillys orforglipron maintenance design Why holding the line after GLP-1 therapy is the next major category 17:30 Amylin Agonists: Cagrelintide vs
Rybelsus (oral semaglutide) is taken as a daily tablet on an empty stomach
For preparation guidance, please refer to our Peptide Reconstitution Guide
US$ 21.16
US$ 21.69
US$ 21.78
US$ 29.24
US$ 21.53
US$ 27.10
US$ 24.58
US$ 22.94
US$ 25.50
US$ 29.40
US$ 20.86
US$ 25.95
